| Management target | Revenue 20.0% |
|---|
| Revenue growth | Reported +51% YoY; organic H1 +23%, gap is inorganic-driven. |
|---|---|
| Margins | Adj EBITDA margin 17% H1 vs 11% last year; +600bps expansion. |
| Order book | Order book not quantified; new ACV TTM ₹93 Cr is proxy. |
| Demand visibility | ARR ₹1,085 Cr (+51%); US flat YoY, Europe/SEA/India improving. |
| Management confidence | Upbeat; declines firm organic acceleration timing, 'few quarters' away. |
Growth
H1 organic revenue rose ₹257→318 Cr (+23%). Inorganic rose ₹101→210 Cr, mostly Session M, so reported growth overstates organic momentum.
Outlook
Reiterates ~20% organic growth with no fiscal year stated. Expects Session M server costs down ~50% by March 2027. Bulk migrations land in FY28-29.
Risks
Session M gross margin is ~51-52% vs core >70%. Migrations run FY28-29. Acquired platforms churn ~10% annually, and organic acceleration is deferred 'a few quarters'.
Earnings Call Transcript filed with BSE, NSE: CAPILLARY. Summary written with AI assistance from the document.
Capillary Technologies India Ltd: key numbers
- Share price
- ₹509.00
- Market cap
- ₹4,056 Cr
- Revenue (annual)
- ₹734.6 Cr
- Net profit (annual)
- ₹52.39 Cr
- P/E (TTM)
- 63.6×Sector 23.8×
- Promoter holding
- 47.23%-4.22% QoQ
- FII holding
- 2.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Capillary Technologies India Ltd
All →Capillary Technologies India Employee Stock Options
Capillary Technologies allotted 94,553 equity shares of ₹2 each upon exercise of vested ESOP 2021 options. The allotment was approved by circular resolution on November 04, 2026.
Capillary Technologies India Business Update
Capillary Technologies announced the strategic shutdown of its China operations due to low growth. Both quantitative and qualitative effects of the restructuring are stated as nil.
Capillary Technologies India Management Change
Capillary Technologies replaced internal auditor Protiviti with Deloitte Touche Tohmatsu India LLP on a 15-month term. The board cited expanding international operations as the reason.
Capillary Technologies India Other Announcement
Capillary Technologies appointed Deloitte Touche Tohmatsu India LLP as Internal Auditor, replacing Protiviti India. The change takes effect November 02, 2026.
Capillary Technologies India Results Update
Capillary announced Q2 FY27 revenue of ₹2,713.5 Mn (+51% YoY) and Adjusted EBITDA of ₹448.6 Mn (+103%). H1 FY27 revenue grew 47% with EBITDA up 116%.
Capillary Technologies India Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,713.5 Mn (+51% YoY), Adj. EBITDA ₹448.6 Mn (17% margin), PAT ₹219.2 Mn. H1 PAT ₹123.7 Mn after ₹333.9 Mn cyber-fraud exceptional loss. Organic NRR 116%.